Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 11Phase 3 9Phase NA 4Phase 1/2 4Phase 4 1Phase 2/3 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 39Other hematologic neoplasm 17Gastrointestinal 17Lymphoid 15Thoracic 13Breast 10Gynecologic 7Myeloid 6Dermatologic 5Genitourinary 4Sarcoma 3Tumor-Agnostic 2Head & Neck 2Plasma cell 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 2mCRPC (Metastatic Castration-resistant Prostate Cancer) 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1High-risk Non-muscle Invasive Bladder Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Injections × Genitourinary × Clear all
NCT07192120 2026-04-09

A Study of MHB048C in Patients With Advanced Solid Tumors

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
200 enrolled
GenitourinaryOther solid neoplasm

mCRPC (Metastatic Castration-resistant Prostate Cancer)

NCT06378242 2024-07-11

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

RemeGen Co., Ltd.

Phase 1/2 Recruiting
24 enrolled
Genitourinary

High-risk Non-muscle Invasive Bladder Cancer

NCT06022757 2024-02-23

KEYNOTE F19

Evopoint Biosciences Inc.

Phase 1/2 Recruiting
204 enrolled
GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡